Systemic Lupus Erythematosus Clinical Trial
Official title:
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in SLE and in CLE (SCLE and/or DLE) Participants Receiving Standard of Care (WILLOW)
The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE; subacute cutaneous lupus erythematosus [SCLE] and/or discoid lupus erythematosus [DLE]) participants in a randomized, double-blind, placebo-controlled, parallel, adaptive and dose-ranging setting. Study Duration: 33 weeks Visit Frequency: every 2 or 4 weeks Enpatoran is not available through an expanded access program.
Status | Recruiting |
Enrollment | 532 |
Est. completion date | August 16, 2024 |
Est. primary completion date | July 8, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Active CLE (SCLE and/or DLE) with a CLE disease area and activity index (CLASI-A) >= 8 - Active SLE with presence of: CLASI-A >= 8 and BILAG 2004 1B, C, D (that is [i.e.], No BILAG 2004 A and No BILAG 2004 >= 2B) or BILAG 2004 >= 1A or 2B and 1 or 2 of the following: Hybrid Safety of Estrogens in Systemic Lupus Erythematosus National Assessment (SELENA)-SLEDAI >= 6 at Screening Visit and confirmed clinical hybrid SELENA-SLEDAI >= 4 (excluding laboratory parameters) at Day 1 Visit and/or CLASI-A >= 8 - Receiving a stable dose of at least one of the following standards of care therapies for lupus: Immunomodulator/immunosuppressant, oral corticosteroids, and/or topical corticosteroids - Other protocol defined inclusion criteria could apply Exclusion Criteria: - Autoimmune or rheumatic disease other than SLE or CLE - Dermatological diseases other than cutaneous manifestations of SLE or CLE - Uncontrolled medical conditions including significant cardiovascular events, active lupus nephritis, and active neurological disorder - Ongoing or active clinically significant viral, bacterial, or fungal infection - History of uncontrolled seizures or other neurological disorder - History of or positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B virus - History of malignancy - Other protocol defined exclusion criteria could apply |
Country | Name | City | State |
---|---|---|---|
Argentina | Buenos Aires Skin | Ciudad Autonoma Buenos Aires | |
Argentina | Centro Dermatologico Schejtman | Ciudad Autonoma Buenos Aires | |
Argentina | Hospital Militar Central Dr. Cosme Argerich | Ciudad Autonoma Buenos Aires | |
Argentina | CINME - Centro De Investigaciones Metabolicas | Ciudad Autonoma de Buenos Aires | |
Argentina | Centro de Investigaciones Medicas Mar del Plata - CIM | Mar del Plata | |
Argentina | Instituto de Reumatologia | Mendoza | |
Argentina | Instituto Medico de la Fundacion Estudios Clinicos | Rosario | |
Argentina | Cordis S.A. | Salta | |
Argentina | Investigaciones Clínicas Salta (ICSAL) | Salta | |
Argentina | Instituto Medico de alta Complejidad San Isidro S.A (IMAC) | San Fernando | |
Argentina | CER San Juan Centro Polivalente de Asistencia e Inv. Clinica | San Juan | |
Argentina | PSORIAHUE-Medicina Interdisciplinar | San Miguel | |
Argentina | Investigaciones Clinicas Tucuman | San Miguel de Tucuman | |
Argentina | Centro de Investigaciones Medicas Tucuman | Tucuman | |
Australia | Box Hill Hospital - PARENT | Caulfield | |
Australia | Monash Medical Centre Clayton | Clayton | |
Australia | Fiona Stanley Hospital - Haematology | Murdoch | |
Australia | Royal Melbourne Hospital - PARENT | Parkville | |
Australia | Westmead Hospital - SUPERSEDED | Westmead | |
Australia | Veracity Clinical Research | Woolloongabba | |
Brazil | Santa Casa de Misericórdia de Belo Horizonte | Belo Horizonte | |
Brazil | Oncovida - Centro de Onco-Hematologia de Mato Grosso | Cuiabá | |
Brazil | CETI - Centro de Estudos em Terapias Inovadoras Ltda. | Curitiba | |
Brazil | Edumed - Educação e Saúde SA | Curitiba | |
Brazil | HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará | Fortaleza | |
Brazil | CMiP - Centro Mineiro de Pesquisa | Juiz de Fora | |
Brazil | Hospital Bruno Born | Lajeado | |
Brazil | Hospital Moinhos de Vento | Porto Alegre | |
Brazil | Clínica SER da Bahia | Salvador | |
Brazil | Fundação Faculdade Regional de Medicina de São José do Rio Preto - CIP - Centro Integrado de Pesquisa | Sao Jose do Rio Preto | |
Brazil | CPCLIN - Centro de Pesquisas Clínicas Ltda. | Sao Paulo | |
Brazil | CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos | São Paulo | |
Bulgaria | DCC 'Sveti Georgi' EOOD - Cardiology Office | Haskovo | |
Bulgaria | Medical center Medconsult Pleven OOD | Pleven | |
Bulgaria | MC Artmed OOD | Plovdiv | |
Bulgaria | DCC 1 - Ruse, EOOD | Ruse | |
Bulgaria | Medical Center-1-Sevlievo EOOD | Sevlievo | |
Bulgaria | DCC "Alexandrovska", EOOD | Sofia | |
Bulgaria | DCC Focus 5 - MEOH OOD | Sofia | |
Bulgaria | Military Medical Academy - MHAT - Sofia - Department of Rheumatology | Sofia | |
Bulgaria | UMHAT "Sv. Ivan Rilski", EAD - Clinic of Rheumatology | Sofia | |
Bulgaria | UMHAT Prof. Dr. Stoyan Kirkovich AD | Stara Zagora | |
Chile | Clínica Alemana de Osorno | Osorno | |
Chile | BioMedica Research Group - Psicomedica Clinical and Research Group | Santiago | |
Chile | CeCim Biocinetic | Santiago | |
Chile | Centro Medico Prosalud | Santiago | |
Chile | CIEC - Centro Internacional de Estudios Clínicos - Valenzuela Y Compania Ltda | Santiago | |
Chile | Dermacross | Santiago | |
China | The First Affiliated Hospital of Baotou Medical College | Baotou | |
China | Peking Union Medical College Hospital - Beijing Union Medical College Hospital | Beijing | |
China | The First Hospital of Jilin University | Changchun | |
China | The 2nd Xiangya Hospital of Central South University | Changsha | |
China | West China Hospital, Sichuan University | Chengdu | |
China | Guangdong Provincial People's Hospital - Oncology | Guangzhou | |
China | The First Affiliated Hospital, Sun Yat-sen University | Guangzhou | |
China | Hainan General Hospital | Haikou | |
China | The Affiliated Hospital of Inner Mongolia Medical University | Hohhot | |
China | The First Affiliated Hospital of Henan University of Science and Technology | Luoyang | |
China | The Second Affiliated Hospital of Nanchang University | Nanchang | |
China | Hospital for Skin Diseases, Chinese Academy of Medical Sciences | Nanjing | |
China | The Affiliated Drum Tower Hospital of Nanjing University | Nanjing | |
China | Huashan Hospital, Fudan University | Shanghai | |
China | Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch | Shanghai | |
China | Ruijin Hospital of Shanghai Jiaotong University School of Medicine | Shanghai | |
China | Shanghai Skin Disease Hospital | Shanghai | |
China | The First Affiliated Hospital of Soochow University | SuZhou | |
China | Tianjin Medical University General Hospital | Tianjin | |
China | The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an | |
Colombia | Centro de Investigacion Medico Asistencial S.A.S | Barranquilla | |
Colombia | Centro de Investigacion en Reumatologia y Especialidades Medicas CIREEM S.A.S. | Bogotá | |
Colombia | Servimed S.A.S. | Bucaramanga | |
Colombia | Centro Integral de Reumatologia del Caribe SAS CIRCARIBE SAS | Medellin | |
Colombia | Healthy Medical Center | Zipaquirá | |
Greece | "Andreas Syggros" Hospital - Department of Dermatology | Athens | |
Greece | General Hospital of Athens Laiko | Athens | |
Greece | General Hospital of Athens Laiko | Athens | |
Greece | University Hospital of Patra | Patra | |
Greece | General Hospital of Thessaloniki "Hippokration" | Thessaloniki | |
Greece | General Hospital Papageorgiou | Thessaloniki | |
Greece | Skin and Venereal Diseases' Hospital | Thessaloniki | |
Israel | Chaim Sheba Medical Center - pt | Ramat Gan | |
Japan | NHO Asahikawa Medical Center - Dept of Gastroenterology | Asahikawa-shi | |
Japan | NHO Chibahigashi National Hospital - Dept of Allergy/Rheumatology | Chiba-shi | |
Japan | St. Luke's International Hospital - Dept of Immunology/Allergy | Chuo-ku | |
Japan | Hiroshima University Hospital - Dept of Rheumatology/Immunology | Hiroshima-shi | |
Japan | Eiraku Clinic - Dept of Rheumatology | Kagoshima-shi | |
Japan | Kanazawa University Hospital - Dept of Rheumatology/Immunology | Kanazawa-shi | |
Japan | Saitama Medical Center - Dept of Rheumatology/Immunology | Kawagoe-shi | |
Japan | Kagawa University Hospital - Dept of Immunology/ Rheumatology | Kita-gun | |
Japan | Toho University Ohashi Medical Center - Dept of Immunology/Rheumatology | Meguro-ku | |
Japan | Hokkaido University Hospital - Dept of Internal Medicine 2(Rheumatology/Immunolog | Sapporo-shi | |
Japan | Tohoku University Hospital - Dept of Hematology/Immunology | Sendai-shi | |
Japan | Ehime University Hospital - Dept of Immunology/Rheumatology | Toon-shi | |
Korea, Republic of | Pusan National University Hospital | Busan | |
Korea, Republic of | Gachon University Gil Medical Center | Incheon | |
Korea, Republic of | Kyung Hee University Hospital at Gangdong: | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Ajou University Hospital | Suwon | |
Mauritius | CAP Research Ltd | Quatre Bornes | |
Mexico | CAIMED Investigacion en salud S.A de C.V. | Ciudad de México | |
Mexico | Consultorio Particular del Dr. Miguel Cortes Hernandez - (dentro del Centro de Especialidades Medicas Vista | Cuernavaca | |
Mexico | Centro de Estudios de Investigacion Basica y Clinica SC | Guadalajara | |
Mexico | Consultorio Médico del Dr. Federico Galván Villegas | Guadalajara | |
Mexico | Diseño y Planeacion en Investigacion Medica S.C. | Guadalajara | |
Mexico | Centro Medico del Angel | Mexicali | |
Mexico | Centro de Investigacion Clínica GRAMEL S.C | Mexico | |
Mexico | Citer, Centro de Investigación Y Tratamiento de Las Enfermedades Reumaticas Sa de Cv | Mexico | |
Mexico | Clinstile, S.A. de C.V. | Mexico | |
Mexico | Consultorio de Reumatologia - Hospital Angeles Lindavista Cons. 445B | Mexico | |
Mexico | Grupo Medico Camino S.C. | Mexico | |
Mexico | AMAF Clinical Research S.C | México | |
Mexico | Centro Regiomontano de Estudios Clínicos Roma S.C. | Monterrey | |
Mexico | CIMAB S.A. de C.V. - Centro de Investigacion Medica Alberto Bazzoni | Torreon | |
Mexico | Medical Care & Research SA de CV | Yucatan | |
Moldova, Republic of | ICS ARENSIA Exploratory Medicine SRL - Republican Clinical Hospital "Timofei Mosneaga" | Chisinau | |
Philippines | Green City Medical Center | Angeles City | |
Philippines | Perpetual Succour Hospital | Cebu City | |
Philippines | Davao Doctors Hospital - Medicine | Davao City | |
Philippines | Iloilo Doctors Hospital | Iloilo City | |
Philippines | Mary Mediatrix Medical Center | Lipa City | |
Philippines | Chinese General Hospital & Medical Center | Manila | |
Philippines | Far Eastern University - Dr. Nicanor Reyes Medical Foundation - Department of Child Health | Quezon City | |
Philippines | Ospital Ng Makati | Quezon City | |
Poland | Nova Reuma Spolka Partnerska | Bialystok | |
Poland | Prywatna Praktyka Lekarska prof Pawel Hrycaj | Koscian | |
Poland | Centrum Medyczne Plejady | Krakow | |
Poland | Centrum Nowoczesnych Terapii Dobry Lekarz | Krakow | |
Poland | Twoja Przychodnia Opolskie Centrum Medyczne | Opole | |
Poland | Twoja Przychodnia PCM | Poznan | |
Poland | Twoja Przychodnia-Szczecinskie Centrum Medyczne | Szczecin | |
Poland | Clinical Best Solutions - Warszawa | Warszawa | |
Romania | Centrul Medical Monza SRL - Arensia Exploratory Medicine | Bucharest | |
Romania | S.C Delta Health Care S.R.L - Ponderas Academic Hospital | Bucuresti | |
Romania | Spitalul Clinic "Sf. Maria" - Clinica de Medicina Interna si Reumatologie | Bucuresti | |
Romania | Spitalul Clinic "Sf. Maria" - parent | Bucuresti | |
Romania | Spitalul Clinic Colentina - parent | Bucuresti | |
Romania | Sc Medaudio-Optica SRL | Ramnicu Valcea | |
Serbia | Institute of Rheumatology | Belgrade | |
Serbia | Institute of Rheumatology- 1 | Belgrade | |
Serbia | Institute of Rheumatology-1 | Belgrade | |
Serbia | University Clinical Center of Serbia - Clinic of Alergology and Imunology | Belgrade | |
Serbia | University Clinical Center Kragujevac | Kragujevac | |
South Africa | Arthritis Clinical Research Trial Unit - Dr CE Spargo and Dr RB Bhorat | Cape Town | |
South Africa | University of Pretoria Clinical Research Unit - Parent | Pretoria | |
South Africa | Naidoo, A - Netcare Umhlanga Hospital | Umhlanga | |
Spain | Hospital General de Castellon - Servicio de Reumatologia | Castelló | |
Spain | Complejo Hospitalario Universitario A Coruña - Servicio de Reumatologia | La Coruña | |
Spain | Hospital Universitario 12 de Octubre - Servicio de Reumatologia | Madrid | |
Spain | Hospital Regional Universitario de Malaga - Reumatology Dept | Málaga | |
Spain | Hospital Universitario Marques de Valdecilla - Servicio de Reumatologia | Santander | |
Spain | Hospital Quironsalud Sagrado Corazon - Reumatologia | Sevilla | |
Spain | Hospital Universitario Dr. Peset - Servicio de Reumatologia | Valencia | |
Spain | Hospital Universitario Rio Hortega - Servicio de Medicina Interna | Valladolid | |
Taiwan | Kaohsiung Chang Gung Memorial Hospital | Kaohsiung | |
Taiwan | Cheng Hsin General Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei City | |
United States | Austin Regional Clinic, P.A. | Austin | Texas |
United States | Bay Area Arthritis and Osteoporosis | Brandon | Florida |
United States | Precision Comprehensive Clinical Research Solutions | Colleyville | Texas |
United States | Ohio State University - CTMO Parent | Columbus | Ohio |
United States | AA MRC LLC Ahmed Arif Medical Research Center | Grand Blanc | Michigan |
United States | Dawes Fretzin Dermatology Group, LLC | Indianapolis | Indiana |
United States | Ramesh C Gupta, MD - Memphis, TN | Memphis | Tennessee |
United States | Advance Medical Research Center | Miami | Florida |
United States | New Horizon Research Center, Inc | Miami | Florida |
United States | Charisma Medical and Research Center | Miami Lakes | Florida |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | HMD Research, LLC | Orlando | Florida |
United States | Across the Life Span | Smithfield | North Carolina |
United States | Jordan Valley Dermatology Center | South Jordan | Utah |
United States | RNA America Health Sciences | Sugar Hill | Georgia |
United States | D&H Tamarac Research Center, LLC | Tamarac | Florida |
United States | Model Research Center, LLC | Tampa | Florida |
United States | University of Toledo - PARENT | Toledo | Ohio |
United States | The Lundquist Institute at Harbor-UCLA Medical Center | Torrance | California |
United States | Rheumatology & Osteoporosis Institute of Oklahoma | Tulsa | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
EMD Serono Research & Development Institute, Inc. | Merck KGaA, Darmstadt, Germany |
United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Greece, Israel, Japan, Korea, Republic of, Mauritius, Mexico, Moldova, Republic of, Philippines, Poland, Romania, Serbia, South Africa, Spain, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cohort A: Percent Change from Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI-A) at Week 16 | Baseline, Week 16 | ||
Primary | Cohort B: British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response at Week 24 | At Week 24 | ||
Secondary | Cohort A and Cohort B: Safety Profile as Assessed by Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), AEs of Special Interest, Clinically Significant Abnormalities in Laboratory Parameters and QT Interval Corrected | Baseline (Day 1) up to End of Safety Follow-up Period (Week 33) | ||
Secondary | Cohort A and Cohort B: Change from Baseline in Cutaneous Lupus Activity Investigator's Global Assessment (CLA-IGA) at Week 16 and Week 24 | Baseline, Week 16 and 24 | ||
Secondary | Cohort A and Cohort B: Change from Baseline in Physician's Global Assessment of Cutaneous Lupus Disease Activity at Week 16 and 24 | Baseline, Week 16 and 24 | ||
Secondary | Cohort B: Participants with British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) Response and with Clinically Meaningful Corticosteroids (CS) Reduction | CS reduction is defined as the reduction of daily prednisone-equivalent dose from >= 10 mg at Day 1 to <= 5 mg by the Week 12 visit and sustained through Week 24. | Day 1 up to Week 24 | |
Secondary | Cohort A: Clinically Meaningful Corticosteroids (CS) Reduction | CS reduction is defined as the reduction of daily prednisone-equivalent dose from >= 10 mg at Day 1 to <= 5 mg by the Week 12 visit and sustained through Week 24. | Day 1 up to Week 24 | |
Secondary | Cohort A: Ocurrence of Cutaneous Lupus Activity Investigator's Global Assessment (CLA-IGA) Score 0 or 1 at Week 16 and Week 24 | At Week 16 and 24 | ||
Secondary | Cohort B: Systemic lupus Erythematosus Responder Index-4 (SRI-4) Response at Week 24 | At Week 24 | ||
Secondary | Cohort B: Lupus Low Disease Activity State (LLDAS) Attainment at Week 24 | At Week 24 | ||
Secondary | Cohort B: Remission Attainment at Week 24 | At Week 24 | ||
Secondary | Cohort B: Change From Baseline in Tender Joint Count and Swollen Joint Count at Week 24 | Baseline, Week 24 | ||
Secondary | Cohort B: Change from Baseline in Physician's Global Assessment at Week 24 | Baseline, Week 24 | ||
Secondary | Cohort B: Time to First Moderate/Severe British Isles Lupus Assessment Group (BILAG) Flare | Day 1 through Week 24 | ||
Secondary | Cohort B: Time to First Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Flare Index (SFI) Severe Flare | Day 1 through Week 24 | ||
Secondary | Cohort A and B: Change from Baseline in Skindex 29+3 Symptom Domain Score at Week 24 | Baseline, Week 24 | ||
Secondary | Cohort A and B: Change from Baseline in the Skindex 29+3 Functioning and Emotion Domain Scores at Week 24 | Baseline, Week 24 | ||
Secondary | Change from Baseline in the Skindex 29+3 Lupus-Specific Domain Score at Week 24 | Baseline, Week 24 | ||
Secondary | Cohort A and B: Change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scores at Week 24 | Baseline, Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
|
Phase 1 | |
Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
Completed |
NCT03802578 -
The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients
|
N/A | |
Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A |